• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

FDA Panel Rejects Use of MDMA for Treatment of PTSD

An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.

Andrew Jacobs
Author: Andrew Jacobs

Written by

Andrew Jacobs

in

Drug Abuse and Traffic, Drugs (Pharmaceuticals), Ecstasy (Drug), Food and Drug Administration, Institute for Clinical and Economic Review, Justice Department, Lykos Therapeutics, Medicine and Health, Mental Health and Disorders, Multidisciplinary Assn for Psychedelic Studies, Placebos, Post-Traumatic Stress Disorder, Psychedelic and Hallucinogenic Drugs, Psychiatry and Psychiatrists, Regulation and Deregulation of Industry, Therapy and Rehabilitation, Veterans
←Alarming Report Warns Of ‘Greatest Threat To American Democracy You’ve Never Heard Of’
Trump Asks For Gag Order To Be Lifted Before Debate With Biden→

More posts

  • Andrea Newman Leaving ‘Chicago Fire’ After 14 Seasons, Victor Teran Named New Showrunner

  • Are the latest Iran talks for real?

  • Appeals court rules that Trump’s asylum ban at the border is illegal

  • Maine governor vetoes statewide pause in new data centers

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube